<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cureus</journal-id><journal-id journal-id-type="iso-abbrev">Cureus</journal-id><journal-id journal-id-type="issn">2168-8184</journal-id><journal-title-group><journal-title>Cureus</journal-title></journal-title-group><issn pub-type="epub">2168-8184</issn><publisher><publisher-name>Cureus</publisher-name><publisher-loc>Palo Alto (CA)</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40190951</article-id><article-id pub-id-type="pmc">PMC11972140</article-id><article-id pub-id-type="doi">10.7759/cureus.80172</article-id><article-categories><subj-group subj-group-type="heading"><subject>Family/General Practice</subject></subj-group><subj-group><subject>Neurology</subject></subj-group><subj-group><subject>Internal Medicine</subject></subj-group></article-categories><title-group><article-title>Effectiveness of Immunosuppressive Therapy in Preventing the Progression of Ocular Myasthenia Gravis to Generalized Myasthenia Gravis: A Systematic Review and Meta-Analysis</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Muacevic</surname><given-names>Alexander</given-names></name></contrib><contrib contrib-type="editor"><name><surname>Adler</surname><given-names>John R</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Nall</surname><given-names>Scott</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Majeed</surname><given-names>Jawaria</given-names></name><xref rid="aff-2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Ahmed Mohsen Alrashidi</surname><given-names>Abdulazizi</given-names></name><xref rid="aff-3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Alhneif</surname><given-names>Mohammad</given-names></name><xref rid="aff-4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Hannan Asghar</surname><given-names>Abdul</given-names></name><xref rid="aff-5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Mubarik</surname><given-names>Abdullah</given-names></name><xref rid="aff-5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Ahmed Mohsen Alrashidi</surname><given-names>Ibrahim</given-names></name><xref rid="aff-6" ref-type="aff">6</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Allahwala</surname><given-names>Danish</given-names></name><xref rid="aff-7" ref-type="aff">7</xref></contrib></contrib-group><aff id="aff-1">
<label>1</label>
Medicine, Central Michigan University (CMU) School of Medicine, Mount Pleasant, USA </aff><aff id="aff-2">
<label>2</label>
Gastroenterology and Hepatology, Nishtar Medical University, Multan, PAK </aff><aff id="aff-3">
<label>3</label>
Health Affairs, Ministry of National Guard, Riyadh, SAU </aff><aff id="aff-4">
<label>4</label>
Neuropathology, University of Texas Health Science Center at San Antonio, San Antonio, USA </aff><aff id="aff-5">
<label>5</label>
Medicine, Quaid-e-Azam Institute of Nursing and Allied Health Sciences, Lahore, PAK </aff><aff id="aff-6">
<label>6</label>
Pharmacy, Al Nakheel Medical Centre, Muqaba, BHR </aff><aff id="aff-7">
<label>7</label>
Nephrology, Fatima Memorial Hospital, Lahore, PAK </aff><author-notes><corresp id="cor1">
Danish Allahwala <email>danishallahwala69@gmail.com</email>
</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>6</day><month>3</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>3</month><year>2025</year></pub-date><volume>17</volume><issue>3</issue><elocation-id>e80172</elocation-id><history><date date-type="accepted"><day>5</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025, Nall et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Nall et al.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xlink:href="https://www.cureus.com/articles/343981-effectiveness-of-immunosuppressive-therapy-in-preventing-the-progression-of-ocular-myasthenia-gravis-to-generalized-myasthenia-gravis-a-systematic-review-and-meta-analysis">This article is available from https://www.cureus.com/articles/343981-effectiveness-of-immunosuppressive-therapy-in-preventing-the-progression-of-ocular-myasthenia-gravis-to-generalized-myasthenia-gravis-a-systematic-review-and-meta-analysis</self-uri><abstract><p>Ocular myasthenia gravis (OMG) is a localized form of myasthenia gravis (MG) that primarily affects the extraocular muscles, causing symptoms such as ptosis and diplopia.&#x000a0;Without treatment, patients with OMG can progress to generalized MG (gMG), which involves systemic muscle weakness and can lead to severe complications. Immunosuppressive therapy aims to modulate the autoimmune response that underlies MG by reducing the production of pathogenic autoantibodies against the acetylcholine receptors (AChRs) or related neuromuscular junction components. This systematic review and meta-analysis evaluated the effectiveness of immunosuppressive therapy in preventing progression from OMG to gMG. A comprehensive literature search was conducted across PubMed, Web of Science, and Embase databases for studies published through January 2025. Ten retrospective observational studies met inclusion criteria, comprising 1,458 participants, with 761 receiving immunosuppression therapy. The meta-analysis revealed that immunosuppressive therapy significantly reduced the risk of generalization compared to control groups (OR: 0.23, 95%CI: 0.15-0.38, I<sup>2</sup>: 34%), representing a 77% decrease in progression rate. Sensitivity analyses demonstrated robust findings, with consistent ORs ranging from 0.21 to 0.27 after sequential removal of individual studies. The funnel plot showed no significant publication bias. However, the review was limited by the retrospective nature of included studies, moderate heterogeneity, and predominant focus on Western populations. These findings support the use of immunosuppressive therapy in preventing OMG progression, though further research through multicenter randomized controlled trials is needed to establish optimal treatment protocols, particularly in Asian populations. Future studies should also investigate biomarkers for treatment response and compare effectiveness between different immunosuppressive regimens.</p></abstract><kwd-group kwd-group-type="author"><kwd>disease progression</kwd><kwd>generalized myasthenia gravis</kwd><kwd>immunosuppressive therapy</kwd><kwd>meta-analysis</kwd><kwd>ocular myasthenia gravis</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction and background</title><p>Ocular myasthenia gravis (OMG) is a subset of myasthenia gravis (MG), a neuromuscular disorder characterized by autoimmune-mediated disruption of the neuromuscular junction [<xref rid="REF1" ref-type="bibr">1</xref>]. OMG accounts for approximately 50-60% of MG cases at onset, with nearly half of these patients progressing to generalized MG (gMG) within two years [<xref rid="REF2" ref-type="bibr">2</xref>]. Patients with OMG present with isolated ocular symptoms, including ptosis and diplopia, caused by the weakness of extraocular muscles [<xref rid="REF1" ref-type="bibr">1</xref>]. Although OMG is generally considered a more localized form of the disease, it is well-documented that a significant proportion of patients progress to gMG within a few years [<xref rid="REF3" ref-type="bibr">3</xref>]. This progression, which affects not only ocular but also bulbar and limb muscles, is associated with more severe symptoms, a higher risk of respiratory involvement, and increased healthcare resource utilization [<xref rid="REF4" ref-type="bibr">4</xref>]. The transition from OMG to gMG occurs in approximately 60-80% of patients within the first two years of diagnosis, highlighting the need for effective strategies to prevent this generalization [<xref rid="REF5" ref-type="bibr">5</xref>].&#x000a0;</p><p>The management of OMG primarily focuses on symptom control, and immunosuppressive therapies have become a cornerstone of treatment. These therapies, which include corticosteroids, azathioprine, mycophenolate mofetil, and tacrolimus, are designed to modulate the immune response and reduce the production of antibodies that impair neuromuscular transmission [<xref rid="REF6" ref-type="bibr">6</xref>,<xref rid="REF7" ref-type="bibr">7</xref>]. While the efficacy of these therapies in improving ocular symptoms has been established, their role in preventing disease progression remains unclear. Although some studies suggest that early use of immunosuppressants may reduce the risk of progression to gMG, other research has failed to show significant differences compared to symptomatic treatment alone [<xref rid="REF8" ref-type="bibr">8</xref>]. The lack of consensus on this issue complicates clinical decision-making and underscores the importance of synthesizing available evidence to guide treatment strategies.&#x000a0;</p><p>Several factors may influence the progression of OMG to gMG, including the severity of ocular symptoms at diagnosis, the presence of acetylcholine receptor antibodies, and the age of onset [<xref rid="REF9" ref-type="bibr">9</xref>]. Additionally, the timing, type, and duration of immunosuppressive therapy may also affect the likelihood of progression. Despite these variables, no large-scale studies have definitively established the optimal approach to preventing generalization in OMG patients [<xref rid="REF10" ref-type="bibr">10</xref>]. Given the variability in treatment responses and the evolving landscape of immunosuppressive options, it seemed important to critically assess the collective evidence through a systematic review and meta-analysis.&#x000a0;</p><p>This study aims to systematically review the available literature on the use of immunosuppressive therapies in OMG and evaluate their effectiveness in preventing the progression to gMG. By pooling data from relevant studies, we hope to clarify the role of immunosuppressants in disease modification and provide evidence-based recommendations to inform clinical practice. Ultimately, this analysis will help improve the management of OMG and potentially alter the course of the disease for many patients at risk of generalization.&#x000a0;</p></sec><sec sec-type="review"><title>Review</title><p>Methodology&#x000a0;</p><p>Literature Search&#x000a0;</p><p>A comprehensive and systematic literature search was conducted to identify relevant studies assessing the impact of immunosuppressant therapies on preventing the progression from OMG to gMG. The search included studies published in English from inception to January 15, 2025. Databases including PubMed, Web of Science, and Embase were queried using a combination of MeSH terms and keywords related to "ocular myasthenia gravis", "immunosuppressant therapies", "generalization", and "disease progression". The search strategy also included terms for specific immunosuppressive agents such as corticosteroids, azathioprine, mycophenolate mofetil, and tacrolimus. A search was also performed in Google Scholar to avoid any article being missed. Additionally, the reference lists of included articles and relevant reviews were hand-searched to ensure no pertinent studies were missed. The search was performed by two authors (AA and MA) independently. Any disagreement between two authors was resolved through discussion or involvement of a third author (SN) if required.&#x000a0;</p><p><italic>Study Selection</italic>&#x000a0;</p><p>Studies were included in the review if they met the following criteria: (1) patients diagnosed with OMG, (2) investigation of immunosuppressant therapies to prevent the progression to gMG, (3) clinical studies including randomized controlled trials (RCTs), cohort studies, and case-control studies, and (4) available data on the rate of generalization to gMG. Exclusion criteria were studies that: (1) did not assess the primary outcome of generalization to gMG, (2) focused solely on non-immunosuppressive treatments, and (3) were review articles, case reports, editorials, and animal studies. Two independent reviewers (JM and IA) screened the titles and abstracts of all records identified in the search. Full-text articles were reviewed for eligibility, and any disagreements were resolved through consensus or discussion with a third reviewer (SN).&#x000a0;</p><p>Quality Assessment&#x000a0;</p><p>The quality of the included studies was assessed using appropriate tools depending on the study design. For RCTs, the Cochrane Risk of Bias tool (The Cochrane Collaboration, London, United Kingdom) was employed, which assesses risk across domains such as selection bias, performance bias, detection bias, and attrition bias. For cohort and case-control studies, the Newcastle-Ottawa Scale (NOS),&#x000a0;an ongoing collaboration between the Universities of Newcastle, Australia, and Ottawa, Canada, was used to evaluate the selection of study participants, comparability of groups, and outcome assessment. Studies were rated as low, moderate, or high risk of bias based on the scoring system of the respective tool. The quality assessment was performed independently by two reviewers, and any discrepancies were resolved by discussion.&#x000a0;</p><p>Data Extraction&#x000a0;</p><p>Data were independently extracted from the included studies by two reviewers (AA and AM) using a standardized data extraction form. The following information was extracted: first author, year of publication, study design, sample size, patient characteristics (e.g., age, gender, duration of OMG), details of the immunosuppressive therapies used, and the reported outcomes regarding the progression to gMG. The primary outcome was the rate of progression from OMG to gMG, defined as the clinical diagnosis of gMG during follow-up.&#x000a0;</p><p>Statistical Analysis&#x000a0;</p><p>The primary outcome of this systematic review and meta-analysis was the rate of generalization to gMG in patients with OMG treated with immunosuppressive therapies. Pooled estimates of the risk of progression were calculated using random-effects models, as we expected some heterogeneity across studies due to differences in study populations and treatments. The odds ratio (OR) with a 95% confidence interval (CI) was used to compare the likelihood of progression to gMG between patients receiving immunosuppressive therapy and those not receiving such treatment. Heterogeneity among studies was assessed using the I&#x000b2; statistic, and potential sources of heterogeneity were explored through subgroup analysis based on factors such as the type of immunosuppressant used and study design. Sensitivity analysis was conducted to examine the robustness of the results by excluding studies with a high risk of bias. All statistical analyses were performed using RevMan Version 5.4.1 (The Cochrane Collaboration) and a p-value of less than 0.05 was considered statistically significant.&#x000a0;</p><p>Results&#x000a0;</p><p>The online systematic search yielded 715 studies. After removing duplicates, 688 studies were initially screened. Full-text screening of 19 studies was done based on inclusion and exclusion criteria. In the end, 10 studies were selected to be part of this meta-analysis comprising a total of 1458 participants, of which 761 subjects received immunosuppression therapy. Figure <xref rid="FIG1" ref-type="fig">1</xref> shows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart of study selection. Table <xref rid="TAB1" ref-type="table">1</xref> presents the characteristics of the included studies. The publication year of the included studies ranged from 2003 to 2024. The majority of the studies were carried out in the United States (n=6). All included studies were retrospective observational. The mean age of the included studies ranged from 48 to 75.9 years. Follow-up of included studies ranged from two years to 10 years.&#x000a0;Table <xref rid="TAB2" ref-type="table">2</xref> presents the quality assessment of the included studies.</p><fig position="anchor" fig-type="figure" id="FIG1"><label>Figure 1</label><caption><title>PRISMA flowchart (study selection process)</title><p>PRISMA:&#x000a0;Preferred Reporting Items for Systematic Reviews and Meta-Analyses</p></caption><graphic xlink:href="cureus-0017-00000080172-i01" position="float"/></fig><table-wrap position="float" id="TAB1"><label>Table 1</label><caption><title>Characteristics of included studies</title></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Author</td><td rowspan="1" colspan="1">Year of publication</td><td rowspan="1" colspan="1">Study Design</td><td rowspan="1" colspan="1">Region</td><td rowspan="1" colspan="1">Groups</td><td rowspan="1" colspan="1">Sample Size</td><td rowspan="1" colspan="1">Mean age</td><td rowspan="1" colspan="1">Number of male participants</td><td rowspan="1" colspan="1">Follow-up duration</td></tr><tr><td rowspan="2" colspan="1">Allen et al. [<xref rid="REF11" ref-type="bibr">11</xref>]</td><td rowspan="2" colspan="1">2009</td><td rowspan="2" colspan="1">Retrospective</td><td rowspan="2" colspan="1">United States</td><td rowspan="1" colspan="1">Immunosuppression</td><td rowspan="1" colspan="1">15</td><td rowspan="2" colspan="1">75.9</td><td rowspan="2" colspan="1">24</td><td rowspan="2" colspan="1">4.5 Years</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">24</td></tr><tr><td rowspan="2" colspan="1">Bhanushalli et al. [<xref rid="REF12" ref-type="bibr">12</xref>]</td><td rowspan="2" colspan="1">2008</td><td rowspan="2" colspan="1">Retrospective</td><td rowspan="2" colspan="1">United States</td><td rowspan="1" colspan="1">Immunosuppression</td><td rowspan="1" colspan="1">27</td><td rowspan="2" colspan="1">52</td><td rowspan="2" colspan="1">19</td><td rowspan="2" colspan="1">3 Years</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">8</td></tr><tr><td rowspan="2" colspan="1">Kupersmith et al. [<xref rid="REF13" ref-type="bibr">13</xref>]</td><td rowspan="2" colspan="1">2003</td><td rowspan="2" colspan="1">Retrospective</td><td rowspan="2" colspan="1">United States</td><td rowspan="1" colspan="1">immunosuppression</td><td rowspan="1" colspan="1">58</td><td rowspan="2" colspan="1">48</td><td rowspan="2" colspan="1">57</td><td rowspan="2" colspan="1">2 Years</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">36</td></tr><tr><td rowspan="2" colspan="1">Kupersmith [<xref rid="REF14" ref-type="bibr">14</xref>]</td><td rowspan="2" colspan="1">2009</td><td rowspan="2" colspan="1">Retrospective</td><td rowspan="2" colspan="1">United States</td><td rowspan="1" colspan="1">Immunosuppression</td><td rowspan="1" colspan="1">55</td><td rowspan="2" colspan="1">54</td><td rowspan="2" colspan="1">55</td><td rowspan="2" colspan="1">7 Years</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">32</td></tr><tr><td rowspan="2" colspan="1">Mee et al. [<xref rid="REF15" ref-type="bibr">15</xref>]</td><td rowspan="2" colspan="1">2003</td><td rowspan="2" colspan="1">Retrospective</td><td rowspan="2" colspan="1">Australia</td><td rowspan="1" colspan="1">Immunosuppression</td><td rowspan="1" colspan="1">12</td><td rowspan="2" colspan="1">55.1</td><td rowspan="2" colspan="1">19</td><td rowspan="2" colspan="1">10 Years</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">22</td></tr><tr><td rowspan="2" colspan="1">Menon et al. [<xref rid="REF16" ref-type="bibr">16</xref>]</td><td rowspan="2" colspan="1">2024</td><td rowspan="2" colspan="1">Retrospective</td><td rowspan="2" colspan="1">Canada</td><td rowspan="1" colspan="1">Immunosuppression</td><td rowspan="1" colspan="1">49</td><td rowspan="2" colspan="1">58.8</td><td rowspan="2" colspan="1">44</td><td rowspan="2" colspan="1">7 Years</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">49</td></tr><tr><td rowspan="2" colspan="1">Monsul et al. [<xref rid="REF17" ref-type="bibr">17</xref>]</td><td rowspan="2" colspan="1">2004</td><td rowspan="2" colspan="1">Retrospective</td><td rowspan="2" colspan="1">United States</td><td rowspan="1" colspan="1">Immunosuppression</td><td rowspan="1" colspan="1">27</td><td rowspan="2" colspan="1">53</td><td rowspan="2" colspan="1">31</td><td rowspan="2" colspan="1">2 Years</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">29</td></tr><tr><td rowspan="2" colspan="1">Nagia et al. [<xref rid="REF18" ref-type="bibr">18</xref>]</td><td rowspan="2" colspan="1">2015</td><td rowspan="2" colspan="1">Retrospective</td><td rowspan="2" colspan="1">United States</td><td rowspan="1" colspan="1">Immunosuppression</td><td rowspan="1" colspan="1">76</td><td rowspan="2" colspan="1">61.5</td><td rowspan="2" colspan="1">106</td><td rowspan="2" colspan="1">2 Years</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">82</td></tr><tr><td rowspan="2" colspan="1">Ruan et al. [<xref rid="REF19" ref-type="bibr">19</xref>]</td><td rowspan="2" colspan="1">2021</td><td rowspan="2" colspan="1">Retrospective</td><td rowspan="2" colspan="1">China</td><td rowspan="1" colspan="1">Immunosuppression</td><td rowspan="1" colspan="1">425</td><td rowspan="2" colspan="1">49</td><td rowspan="2" colspan="1">443</td><td rowspan="2" colspan="1">2 Years</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">388</td></tr><tr><td rowspan="2" colspan="1">Zach et al. [<xref rid="REF20" ref-type="bibr">20</xref>]</td><td rowspan="2" colspan="1">2013</td><td rowspan="2" colspan="1">Retrospective</td><td rowspan="2" colspan="1">Austria</td><td rowspan="1" colspan="1">Immunosuppression</td><td rowspan="1" colspan="1">17</td><td rowspan="2" colspan="1">54</td><td rowspan="2" colspan="1">24</td><td rowspan="2" colspan="1">2 Years</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">27</td></tr></tbody></table></table-wrap><table-wrap position="float" id="TAB2"><label>Table 2</label><caption><title>Quality assessment of included studies</title></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Study details</td><td rowspan="1" colspan="1">Selection</td><td rowspan="1" colspan="1">Comparability</td><td rowspan="1" colspan="1">Assessment</td><td rowspan="1" colspan="1">Overall</td></tr><tr><td rowspan="1" colspan="1">Allen et al., 2009 [<xref rid="REF11" ref-type="bibr">11</xref>]</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">Good</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Bhanushalli et al., 2008 [<xref rid="REF12" ref-type="bibr">12</xref>]</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Good</td></tr><tr><td rowspan="1" colspan="1">Kupersmith et al., 2003 [<xref rid="REF13" ref-type="bibr">13</xref>]</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">Good</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Kupersmith, 2009 [<xref rid="REF14" ref-type="bibr">14</xref>]</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Good</td></tr><tr><td rowspan="1" colspan="1">Mee et al., 2003 [<xref rid="REF15" ref-type="bibr">15</xref>]</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Good</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Menon et al., 2024 [<xref rid="REF16" ref-type="bibr">16</xref>]</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Good</td></tr><tr><td rowspan="1" colspan="1">Monsul et al., 2004 [<xref rid="REF17" ref-type="bibr">17</xref>]</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">Fair</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Nagia et al., 2015 [<xref rid="REF18" ref-type="bibr">18</xref>]</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">Fair</td></tr><tr><td rowspan="1" colspan="1">Ruan et al., 2021 [<xref rid="REF19" ref-type="bibr">19</xref>]</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Good</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Zach et al., 2013 [<xref rid="REF20" ref-type="bibr">20</xref>]</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Good</td></tr></tbody></table></table-wrap><p>Effect of Immunosuppressant on the Generalization Rate&#x000a0;</p><p>A comparison of the effect of immunosuppression treatment and control on the rate of generalization is presented in Figure <xref rid="FIG2" ref-type="fig">2</xref>. The odds of developing generalization were significantly lower in patients receiving immunosuppressants compared to control groups (OR: 0.23, 95%CI: 0.15 to 0.38, I<sup>2</sup>: 34%), showing that immunosuppressant therapy decreased the generalization rate by 77%.&#x000a0;</p><fig position="anchor" fig-type="figure" id="FIG2"><label>Figure 2</label><caption><title>Effect of immunosuppressants on generalization</title><p>References: [<xref rid="REF11" ref-type="bibr">11</xref>-<xref rid="REF20" ref-type="bibr">20</xref>]</p></caption><graphic xlink:href="cureus-0017-00000080172-i02" position="float"/></fig><p>Sensitivity Analysis and Publication Bias&#x000a0;</p><p>A sensitivity analysis was conducted to assess the robustness of the findings comparing immunosuppressant therapy to control for the outcome of generalization, and the findings are represented in Table <xref rid="TAB3" ref-type="table">3</xref>. Each study was sequentially removed, and the OR remained consistent, ranging from 0.21 to 0.27, with CIs overlapping. The sensitivity analysis revealed that removing Mee et al.'s study reduced heterogeneity to 12%, suggesting it was a key contributor to variability [<xref rid="REF15" ref-type="bibr">15</xref>]. Despite this, the OR remained stable, ranging from 0.21 to 0.27, with overlapping CIs, indicating a consistent treatment effect of immunosuppressant therapy versus control on generalization. This suggests that while Mee et al.'s study [<xref rid="REF15" ref-type="bibr">15</xref>] contributed to heterogeneity, its exclusion did not significantly alter the overall conclusions, reinforcing the robustness of the findings. The funnel plot shown in Figure <xref rid="FIG3" ref-type="fig">3</xref> appears to be relatively symmetrical, with studies distributed evenly around the central effect estimate. There is no clear evidence of asymmetry, which suggests that publication bias is unlikely. Additionally, the presence of studies with larger standard errors (smaller sample sizes) on both sides of the plot further supports the absence of significant publication bias.&#x000a0;</p><table-wrap position="float" id="TAB3"><label>Table 3</label><caption><title>Sensitivity analysis (removing one study at a time)</title><p>OR: Odds ratio; CI: Confidence interval</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Study details</td><td rowspan="1" colspan="1">OR (95% CI)</td><td rowspan="1" colspan="1">I<sup>2</sup>
</td></tr><tr><td rowspan="1" colspan="1">Allen et al., 2009 [<xref rid="REF11" ref-type="bibr">11</xref>]</td><td rowspan="1" colspan="1">0.25 (0.14, 0.39)</td><td rowspan="1" colspan="1">37%</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Bhanushalli et al., 2008 [<xref rid="REF12" ref-type="bibr">12</xref>]</td><td rowspan="1" colspan="1">0.22 (0.14, 0.36)</td><td rowspan="1" colspan="1">39%</td></tr><tr><td rowspan="1" colspan="1">Kupersmith et al., 2003 [<xref rid="REF13" ref-type="bibr">13</xref>]</td><td rowspan="1" colspan="1">0.25 (0.15, 0.41)</td><td rowspan="1" colspan="1">36%</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Kupersmith, 2009 [<xref rid="REF14" ref-type="bibr">14</xref>]</td><td rowspan="1" colspan="1">0.25 (0.15, 0.41)</td><td rowspan="1" colspan="1">36%</td></tr><tr><td rowspan="1" colspan="1">Mee et al., 2003 [<xref rid="REF15" ref-type="bibr">15</xref>]</td><td rowspan="1" colspan="1">0.27 (0.19, 0.39)</td><td rowspan="1" colspan="1">12%</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Menon et al., 2024 [<xref rid="REF16" ref-type="bibr">16</xref>]</td><td rowspan="1" colspan="1">0.21 (0.12, 0.35)</td><td rowspan="1" colspan="1">35%</td></tr><tr><td rowspan="1" colspan="1">Monsul et al., 2004 [<xref rid="REF17" ref-type="bibr">17</xref>]</td><td rowspan="1" colspan="1">0.23 (0.14, 0.38)</td><td rowspan="1" colspan="1">42%</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Nagia et al., 2015 [<xref rid="REF18" ref-type="bibr">18</xref>]</td><td rowspan="1" colspan="1">0.21 (0.13, 0.33)</td><td rowspan="1" colspan="1">28%</td></tr><tr><td rowspan="1" colspan="1">Ruan et al., 2021 [<xref rid="REF19" ref-type="bibr">19</xref>]</td><td rowspan="1" colspan="1">0.21 (0.11, 0.38)</td><td rowspan="1" colspan="1">41%</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Zach et al., 2013 [<xref rid="REF20" ref-type="bibr">20</xref>]</td><td rowspan="1" colspan="1">0.24 (0.16, 0.39)</td><td rowspan="1" colspan="1">34%</td></tr></tbody></table></table-wrap><fig position="anchor" fig-type="figure" id="FIG3"><label>Figure 3</label><caption><title>Funnel plot (showing publication bias)</title></caption><graphic xlink:href="cureus-0017-00000080172-i03" position="float"/></fig><p>Discussion&#x000a0;</p><p>The aim of this systematic review and meta-analysis was to evaluate the effect of immunosuppressant therapy on the risk of secondary generalization in patients with OMG. The findings suggest that immunosuppressants can significantly reduce this risk. A meta-analysis by Li et al., which included eight studies, reported similar results [<xref rid="REF21" ref-type="bibr">21</xref>]. Moderate heterogeneity was observed in our study, prompting a sensitivity analysis to identify its source. The analysis revealed that Mee et al.'s study contributed the most to heterogeneity, likely due to its longer follow-up period.&#x000a0;</p><p>Immunosuppressants may prevent secondary generalization in OMG by modulating the autoimmune response at multiple levels. They help reduce the production of pathogenic autoantibodies, particularly those targeting the acetylcholine receptors (AChRs) at the neuromuscular junction, thereby limiting the immune-mediated attack on muscle function [<xref rid="REF22" ref-type="bibr">22</xref>]. Additionally, these agents suppress T-cell activation and cytokine release, dampening the inflammatory cascade that contributes to disease progression. By stabilizing neuromuscular transmission and preventing widespread synaptic dysfunction, immunosuppressants may slow or halt the transition from OMG to gMG, thereby preserving muscle function and reducing symptom burden [<xref rid="REF23" ref-type="bibr">23</xref>]. Although the autoimmune nature of MG is well established, evidence supporting the protective role of immunosuppressive therapy in OMG remains limited. This gap in research is primarily due to challenges in conducting controlled studies within the OMG population. For instance, a past randomized clinical trial designed to evaluate the effectiveness of prednisone in OMG had to be discontinued prematurely due to enrollment difficulties, ultimately including only 11 participants [<xref rid="REF24" ref-type="bibr">24</xref>].&#x000a0;</p><p>The optimal duration of immunosuppression for managing OMG remains unclear, with treatment duration varying across studies. In a study by Sommer et al., patients received prednisolone for an average of 32.3 months, while azathioprine therapy lasted approximately 43.7 months [<xref rid="REF25" ref-type="bibr">25</xref>]. Similarly, Zach et al. recommended a minimum treatment duration of three months with prednisolone [<xref rid="REF20" ref-type="bibr">20</xref>]. However, long-term immunosuppression must be carefully balanced against potential adverse effects, including infection risk, metabolic complications, and drug-specific toxicities [<xref rid="REF16" ref-type="bibr">16</xref>]. Further research is needed to establish standardized treatment duration guidelines, optimize tapering strategies, and determine the most effective maintenance regimens for preventing disease progression while minimizing side effects. Large-scale, multicenter RCTs are needed to confirm the protective role of immunosuppression in preventing generalization. Additionally, studies exploring biomarkers that predict treatment response could help in patient stratification and individualized therapy. Comparative effectiveness research between different immunosuppressants and combination regimens may provide further insights. Long-term follow-up studies are also essential to assess relapse rates and the feasibility of tapering or discontinuing therapy in controlled disease states, ultimately guiding clinical decision-making.&#x000a0;</p><p>This meta-analysis has several limitations. First, all included studies were conducted in developed countries, primarily in the United States. There is a notable lack of research from Asian, African, and other populations, limiting the generalizability of findings, as previous studies have suggested a lower generalization rate in OMG patients from these regions [<xref rid="REF26" ref-type="bibr">26</xref>]. Second, moderate heterogeneity was observed across studies, but subgroup analysis could not be performed due to insufficient data. Lastly, all included studies were retrospective observational in design, inherently prone to selection bias and confounding. To validate the role of immunosuppressants, particularly in mild cases and at low doses, well-designed prospective cohort studies and multicenter RCTs are essential.&#x000a0;</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>This meta-analysis demonstrates that immunosuppressive therapy significantly reduces the risk of generalization from OMG to gMG, with a steep decrease in progression rate compared to controls. The findings were robust across sensitivity analyses, with minimal evidence of publication bias. However, the review's limitations include a reliance on retrospective studies primarily from Western populations and moderate heterogeneity across studies. Future research should focus on conducting multicenter RCTs, particularly in Asian populations, to establish optimal treatment protocols and duration. Additionally, studies exploring biomarkers for treatment response and comparative effectiveness between different immunosuppressive regimens are needed. Despite these limitations, the evidence supports the use of immunosuppressive therapy in preventing disease progression in OMG patients.</p></sec></body><back><fn-group content-type="conflict"><title>Disclosures</title><fn fn-type="COI-statement"><p><bold>Conflicts of interest:</bold> In compliance with the ICMJE uniform disclosure form, all authors declare the following:</p><p><bold>Payment/services info:</bold> All authors have declared that no financial support was received from any organization for the submitted work.</p><p><bold>Financial relationships:</bold> All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.</p><p><bold>Other relationships:</bold> All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</p></fn></fn-group><fn-group content-type="other"><title>Author Contributions</title><fn fn-type="other"><p><bold>Concept and design:</bold>&#x000a0; Danish Allahwala, Scott Nall</p><p><bold>Acquisition, analysis, or interpretation of data:</bold>&#x000a0; Danish Allahwala, Mohammad Alhneif , Scott Nall, Abdulazizi Ahmed Mohsen Alrashidi, Jawaria Majeed, Ibrahim Ahmed Mohsen Alrashidi, Abdul Hannan Asghar, Abdullah Mubarik</p><p><bold>Drafting of the manuscript:</bold>&#x000a0; Danish Allahwala, Mohammad Alhneif , Abdulazizi Ahmed Mohsen Alrashidi, Jawaria Majeed, Ibrahim Ahmed Mohsen Alrashidi, Abdul Hannan Asghar, Abdullah Mubarik</p><p><bold>Critical review of the manuscript for important intellectual content:</bold>&#x000a0; Danish Allahwala, Scott Nall</p></fn></fn-group><ref-list><title>References</title><ref id="REF1"><label>1</label><element-citation publication-type="journal"><article-title>Ocular myasthenia gravis: a current overview</article-title><source>Eye Brain</source><person-group>
<name><surname>Behbehani</surname><given-names>R</given-names></name>
</person-group><fpage>1</fpage><lpage>13</lpage><volume>15</volume><year>2023</year><pub-id pub-id-type="pmid">36778719</pub-id>
</element-citation></ref><ref id="REF2"><label>2</label><element-citation publication-type="journal"><article-title>Ocular myasthenia gravis: a review and practical guide for clinicians</article-title><source>Clin Exp Optom</source><person-group>
<name><surname>Shuey</surname><given-names>NH</given-names></name>
</person-group><fpage>205</fpage><lpage>213</lpage><volume>105</volume><year>2022</year><pub-id pub-id-type="pmid">35157811</pub-id>
</element-citation></ref><ref id="REF3"><label>3</label><element-citation publication-type="journal"><article-title>Immunotherapy for ocular myasthenia gravis: an observational study in Japan</article-title><source>Ther Adv Neurol Disord</source><person-group>
<name><surname>Narita</surname><given-names>T</given-names></name>
<name><surname>Nakane</surname><given-names>S</given-names></name>
<name><surname>Nagaishi</surname><given-names>A</given-names></name>
<etal/>
</person-group><fpage>17562864231163819</fpage><volume>16</volume><year>2023</year><pub-id pub-id-type="pmid">37051222</pub-id>
</element-citation></ref><ref id="REF4"><label>4</label><element-citation publication-type="journal"><article-title>Recommendations for the management of myasthenia gravis in Belgium</article-title><source>Acta Neurol Belg</source><person-group>
<name><surname>De Bleecker</surname><given-names>JL</given-names></name>
<name><surname>Remiche</surname><given-names>G</given-names></name>
<name><surname>Alonso-Jim&#x000e9;nez</surname><given-names>A</given-names></name>
<name><surname>Van Parys</surname><given-names>V</given-names></name>
<name><surname>Bissay</surname><given-names>V</given-names></name>
<name><surname>Delstanche</surname><given-names>S</given-names></name>
<name><surname>Claeys</surname><given-names>KG</given-names></name>
</person-group><fpage>1371</fpage><lpage>1383</lpage><volume>124</volume><year>2024</year><pub-id pub-id-type="pmid">38649556</pub-id>
</element-citation></ref><ref id="REF5"><label>5</label><element-citation publication-type="journal"><article-title>Risk factors for generalization in patients with ocular myasthenia gravis: a multicenter retrospective cohort study</article-title><source>Neurol Ther</source><person-group>
<name><surname>Guo</surname><given-names>RJ</given-names></name>
<name><surname>Gao</surname><given-names>T</given-names></name>
<name><surname>Ruan</surname><given-names>Z</given-names></name>
<etal/>
</person-group><fpage>73</fpage><lpage>86</lpage><volume>11</volume><year>2022</year><pub-id pub-id-type="pmid">34729706</pub-id>
</element-citation></ref><ref id="REF6"><label>6</label><element-citation publication-type="journal"><article-title>Maintenance immunosuppression in myasthenia gravis, an update</article-title><source>J Neurol Sci</source><person-group>
<name><surname>Morren</surname><given-names>J</given-names></name>
<name><surname>Li</surname><given-names>Y</given-names></name>
</person-group><fpage>116648</fpage><volume>410</volume><year>2020</year><pub-id pub-id-type="pmid">31901719</pub-id>
</element-citation></ref><ref id="REF7"><label>7</label><element-citation publication-type="journal"><article-title>Myasthenia gravis. Update on diagnosis and therapy</article-title><source>Med Clin (Barc)</source><person-group>
<name><surname>Garc&#x000ed;a Est&#x000e9;vez</surname><given-names>DA</given-names></name>
<name><surname>Pardo Fern&#x000e1;ndez</surname><given-names>J</given-names></name>
</person-group><fpage>119</fpage><lpage>127</lpage><volume>161</volume><year>2023</year><pub-id pub-id-type="pmid">37248131</pub-id>
</element-citation></ref><ref id="REF8"><label>8</label><element-citation publication-type="journal"><article-title>Diagnosis and management of myasthenia gravis</article-title><source>Continuum (Minneap Minn)</source><person-group>
<name><surname>Hehir MK</surname><given-names>2nd</given-names></name>
<name><surname>Li</surname><given-names>Y</given-names></name>
</person-group><fpage>1615</fpage><lpage>1642</lpage><volume>28</volume><year>2022</year><pub-id pub-id-type="pmid">36537972</pub-id>
</element-citation></ref><ref id="REF9"><label>9</label><element-citation publication-type="journal"><article-title>Factors affecting outcome in ocular myasthenia gravis</article-title><source>Int J Neurosci</source><person-group>
<name><surname>Mazzoli</surname><given-names>M</given-names></name>
<name><surname>Ariatti</surname><given-names>A</given-names></name>
<name><surname>Valzania</surname><given-names>F</given-names></name>
<name><surname>Kaleci</surname><given-names>S</given-names></name>
<name><surname>Tondelli</surname><given-names>M</given-names></name>
<name><surname>Nichelli</surname><given-names>PF</given-names></name>
<name><surname>Galassi</surname><given-names>G</given-names></name>
</person-group><fpage>15</fpage><lpage>24</lpage><volume>128</volume><year>2018</year><pub-id pub-id-type="pmid">28625092</pub-id>
</element-citation></ref><ref id="REF10"><label>10</label><element-citation publication-type="journal"><article-title>Ocular manifestation and generalization after ocular onset in ocular myasthenia gravis: a 5-year analysis</article-title><source>Asian Pac J Allergy Immunol</source><person-group>
<name><surname>Kemchoknatee</surname><given-names>P</given-names></name>
<name><surname>Arepagorn</surname><given-names>A</given-names></name>
<name><surname>Srisombut</surname><given-names>T</given-names></name>
</person-group><year>2021</year></element-citation></ref><ref id="REF11"><label>11</label><element-citation publication-type="journal"><article-title>Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis</article-title><source>Muscle Nerve</source><person-group>
<name><surname>Allen</surname><given-names>JA</given-names></name>
<name><surname>Scala</surname><given-names>S</given-names></name>
<name><surname>Jones</surname><given-names>HR</given-names></name>
</person-group><fpage>379</fpage><lpage>384</lpage><volume>41</volume><year>2010</year><pub-id pub-id-type="pmid">19918767</pub-id>
</element-citation></ref><ref id="REF12"><label>12</label><element-citation publication-type="journal"><article-title>Treatment of ocular symptoms in myasthenia gravis</article-title><source>Neurology</source><person-group>
<name><surname>Bhanushali</surname><given-names>MJ</given-names></name>
<name><surname>Wuu</surname><given-names>J</given-names></name>
<name><surname>Benatar</surname><given-names>M</given-names></name>
</person-group><fpage>1335</fpage><lpage>1341</lpage><volume>71</volume><year>2008</year><pub-id pub-id-type="pmid">18936425</pub-id>
</element-citation></ref><ref id="REF13"><label>13</label><element-citation publication-type="journal"><article-title>Development of generalized disease at 2 years in patients with ocular myasthenia gravis</article-title><source>Arch Neurol</source><person-group>
<name><surname>Kupersmith</surname><given-names>MJ</given-names></name>
<name><surname>Latkany</surname><given-names>R</given-names></name>
<name><surname>Homel</surname><given-names>P</given-names></name>
</person-group><fpage>243</fpage><lpage>248</lpage><volume>60</volume><year>2003</year><pub-id pub-id-type="pmid">12580710</pub-id>
</element-citation></ref><ref id="REF14"><label>14</label><element-citation publication-type="journal"><article-title>Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up</article-title><source>J Neurol</source><person-group>
<name><surname>Kupersmith</surname><given-names>MJ</given-names></name>
</person-group><fpage>1314</fpage><lpage>1320</lpage><volume>256</volume><year>2009</year><pub-id pub-id-type="pmid">19377863</pub-id>
</element-citation></ref><ref id="REF15"><label>15</label><element-citation publication-type="journal"><article-title>Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis</article-title><source>J Neuroophthalmol</source><person-group>
<name><surname>Mee</surname><given-names>J</given-names></name>
<name><surname>Paine</surname><given-names>M</given-names></name>
<name><surname>Byrne</surname><given-names>E</given-names></name>
<name><surname>King</surname><given-names>J</given-names></name>
<name><surname>Reardon</surname><given-names>K</given-names></name>
<name><surname>O'Day</surname><given-names>J</given-names></name>
</person-group><fpage>251</fpage><lpage>255</lpage><volume>23</volume><year>2003</year><pub-id pub-id-type="pmid">14663303</pub-id>
</element-citation></ref><ref id="REF16"><label>16</label><element-citation publication-type="journal"><article-title>Effect of immunosuppression in risk of developing generalized symptoms in ocular myasthenia gravis: a retrospective cohort study</article-title><source>Neurology</source><person-group>
<name><surname>Menon</surname><given-names>D</given-names></name>
<name><surname>Alharbi</surname><given-names>M</given-names></name>
<name><surname>Katzberg</surname><given-names>HD</given-names></name>
<name><surname>Bril</surname><given-names>V</given-names></name>
<name><surname>Mendoza</surname><given-names>MG</given-names></name>
<name><surname>Barnett-Tapia</surname><given-names>C</given-names></name>
</person-group><fpage>0</fpage><volume>103</volume><year>2024</year></element-citation></ref><ref id="REF17"><label>17</label><element-citation publication-type="journal"><article-title>The effect of prednisone on the progression from ocular to generalized myasthenia gravis</article-title><source>J Neurol Sci</source><person-group>
<name><surname>Monsul</surname><given-names>NT</given-names></name>
<name><surname>Patwa</surname><given-names>HS</given-names></name>
<name><surname>Knorr</surname><given-names>AM</given-names></name>
<name><surname>Lesser</surname><given-names>RL</given-names></name>
<name><surname>Goldstein</surname><given-names>JM</given-names></name>
</person-group><fpage>131</fpage><lpage>133</lpage><volume>217</volume><year>2004</year><pub-id pub-id-type="pmid">14706214</pub-id>
</element-citation></ref><ref id="REF18"><label>18</label><element-citation publication-type="journal"><article-title>Prognosis of ocular myasthenia gravis: retrospective multicenter analysis</article-title><source>Ophthalmology</source><person-group>
<name><surname>Nagia</surname><given-names>L</given-names></name>
<name><surname>Lemos</surname><given-names>J</given-names></name>
<name><surname>Abusamra</surname><given-names>K</given-names></name>
<name><surname>Cornblath</surname><given-names>WT</given-names></name>
<name><surname>Eggenberger</surname><given-names>ER</given-names></name>
</person-group><fpage>1517</fpage><lpage>1521</lpage><volume>122</volume><year>2015</year><pub-id pub-id-type="pmid">25892018</pub-id>
</element-citation></ref><ref id="REF19"><label>19</label><element-citation publication-type="journal"><article-title>Association of immunosuppression treatment with generalization among patients with ocular myasthenia gravis: a&#x000a0;propensity score analysis</article-title><source>Eur J Neurol</source><person-group>
<name><surname>Ruan</surname><given-names>Z</given-names></name>
<name><surname>Guo</surname><given-names>R</given-names></name>
<name><surname>Zhou</surname><given-names>H</given-names></name>
<etal/>
</person-group><fpage>1805</fpage><lpage>1814</lpage><volume>29</volume><year>2022</year><pub-id pub-id-type="pmid">35188698</pub-id>
</element-citation></ref><ref id="REF20"><label>20</label><element-citation publication-type="journal"><article-title>The effect of early prednisolone treatment on the generalization rate in ocular myasthenia gravis</article-title><source>Eur J Neurol</source><person-group>
<name><surname>Zach</surname><given-names>H</given-names></name>
<name><surname>Cetin</surname><given-names>H</given-names></name>
<name><surname>Hilger</surname><given-names>E</given-names></name>
<etal/>
</person-group><fpage>708</fpage><lpage>713</lpage><volume>20</volume><year>2013</year><pub-id pub-id-type="pmid">23279780</pub-id>
</element-citation></ref><ref id="REF21"><label>21</label><element-citation publication-type="journal"><article-title>Do early prednisolone and other immunosuppressant therapies prevent generalization in ocular myasthenia gravis in Western populations: a systematic review and meta-analysis</article-title><source>Ther Adv Neurol Disord</source><person-group>
<name><surname>Li</surname><given-names>M</given-names></name>
<name><surname>Ge</surname><given-names>F</given-names></name>
<name><surname>Guo</surname><given-names>R</given-names></name>
<etal/>
</person-group><fpage>1756286419876521</fpage><volume>12</volume><year>2019</year><pub-id pub-id-type="pmid">35173803</pub-id>
</element-citation></ref><ref id="REF22"><label>22</label><element-citation publication-type="journal"><article-title>Myasthenia gravis: pathogenic effects of autoantibodies on neuromuscular architecture</article-title><source>Cells</source><person-group>
<name><surname>Koneczny</surname><given-names>I</given-names></name>
<name><surname>Herbst</surname><given-names>R</given-names></name>
</person-group><fpage>671</fpage><volume>8</volume><year>2019</year><pub-id pub-id-type="pmid">31269763</pub-id>
</element-citation></ref><ref id="REF23"><label>23</label><element-citation publication-type="journal"><article-title>Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations</article-title><source>J Clin Med</source><person-group>
<name><surname>Dresser</surname><given-names>L</given-names></name>
<name><surname>Wlodarski</surname><given-names>R</given-names></name>
<name><surname>Rezania</surname><given-names>K</given-names></name>
<name><surname>Soliven</surname><given-names>B</given-names></name>
</person-group><fpage>2235</fpage><volume>10</volume><year>2021</year><pub-id pub-id-type="pmid">34064035</pub-id>
</element-citation></ref><ref id="REF24"><label>24</label><element-citation publication-type="journal"><article-title>Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): a randomized, controlled trial</article-title><source>Muscle Nerve</source><person-group>
<name><surname>Benatar</surname><given-names>M</given-names></name>
<name><surname>Mcdermott</surname><given-names>MP</given-names></name>
<name><surname>Sanders</surname><given-names>DB</given-names></name>
<etal/>
</person-group><fpage>363</fpage><lpage>369</lpage><volume>53</volume><year>2016</year><pub-id pub-id-type="pmid">26179124</pub-id>
</element-citation></ref><ref id="REF25"><label>25</label><element-citation publication-type="journal"><article-title>Ocular myasthenia: diagnostic and therapeutic problems</article-title><source>Acta Neurol Scand</source><person-group>
<name><surname>Evoli</surname><given-names>A</given-names></name>
<name><surname>Tonali</surname><given-names>P</given-names></name>
<name><surname>Bartoccioni</surname><given-names>E</given-names></name>
<name><surname>Lo Monaco</surname><given-names>M</given-names></name>
</person-group><fpage>31</fpage><lpage>35</lpage><volume>77</volume><year>1988</year><pub-id pub-id-type="pmid">3354309</pub-id>
</element-citation></ref><ref id="REF26"><label>26</label><element-citation publication-type="journal"><article-title>Long-term outcome of 424 childhood-onset myasthenia gravis patients</article-title><source>J Neurol</source><person-group>
<name><surname>Gui</surname><given-names>M</given-names></name>
<name><surname>Luo</surname><given-names>X</given-names></name>
<name><surname>Lin</surname><given-names>J</given-names></name>
<etal/>
</person-group><fpage>823</fpage><lpage>830</lpage><volume>262</volume><year>2015</year><pub-id pub-id-type="pmid">25588729</pub-id>
</element-citation></ref></ref-list></back></article>